VV
�� !"#$%&'()*+,Incont Pelvic Floor Dysfunct 2009; 3(4):99-103
�� !"#$%&'()*+,-./0
oÉéçêí=Ñêçã=_ÉåáÖå=mêçëí~íáÅ=eóéÉêéä~ëá~LiçïÉê=rêáå~êó=qê~Åí
póãéíçãë=`çããáííÉÉ
��
�� !"#$%&'()
�� !"#$%&'(613�� !"#�!$%&6�� !"#$%&'(�� �� !"#E-mail: [email protected]
��
��
�� !"#$Ebenign prostatic hyperplasia, BPHF�� !"#$
�� !"#$%&'()*+,-./012*+-3456718
�� !"#$�� !"#$%E�� F�� !"#$%&'��
�� !"#$%&'()*+,-./01234567&(89:
�� !"#$%&'()*+,-./0!1230!45167
�� !"#$%&'()*+,-./0123456789$%:
�� !"#$%&'()*+,-./"#0123)456789
�� !"#$%&'()*+,-.%/01
�� !"#$%&'()*+,-./01234��5 67
�� !"#$%&'()*+,��-./0,12345615��
�� !"#$%�&'()*+!,-.*+/012345678
�� !"#$%&'()*+,-./012325�� !"#$%
�� 5�� !"#$ 30�� !"#$%&'()*+,-./ 5
�30�� !"#$%&'()*+,-./0123456789:
�� !"#$%&'()*+,-./01234056789:
�� !"#$%&'()*%+,�-./012%34567%8
��
�� !"#EGuidelinesF�� !
�� !"#$%&'()*+�,-./012340&567
�� !"#$%&'()*+,-./0&12345(6789:
�� !"#$%&'()2005 ICS Jumadilova Z�� !"#$%&
�� !"#$%&'()*Eoveractive bladder, OABF�� !"#$
�� !"#47%�� !"#$%&'("36%�� !"#$%&
�� !"#$%9%�� !"#$%&'()*+8%�� !"#
�� !"#$xPleil, 2005z�� !"#$%&'()*+,-./(
�� !"#$%&'()*+,
�� !"#$
�� !"#$%&!'()*+,-./012345067
�� !"#$%&'()*+,-./0123456789:;<
�� !"#$ %&'()EprostatismF�� !"#$%&'()*
�� !"#$%&'()*+,-./0��123456 7"(
�� !"#$%Ebenign prostatic enlargement, BPEF�� !"#$%
�Ebenign prostatic obstruction, BPOF�� !"#$%&'()*+,)
�� !"�#$%&'()*+,-./012345678,9:
�� !"#$%&'()*+,� !&'(-./001� !"
�� !"#$%&'()*!"Ebladder outlet obstruction, BOOF��
�� !"#$%&'()*+,-./01234567#$%&'
�� !"#$%&'()*+,-.$/012&34"#,56$
�� !"#$%&'()*+,-./0123&,456789:
�� !"#$%& '()*+,- './012345678
�� !"#$%&'()*+,-./012xBarendrecht et al, 2008;
Martin and de la Rosette, 2009z�
�� !"#$%&'()*+,-./0123
�� !"#$%&'()*+,-./0123456789:
�� !"#$%&'()*+,-./0123��456ELUTS
severityF�� !"Ebother scoreF�� !"Edigital rectal examination,
DREF�� !"#$%Eprostate-specific antigen, PSAF�� EurinalysisF
�� !"Evoiding diaryF�� !"#$%&'()*+,-�./0
�� !"#$%&'()*Einternational prostate symptom score, IPSSF
�� � 8�� !"#$%&'()*+,"-./0123Emaxi-
mum flow rate, QmaxF�� !"Eflow patternF�� !Eresidual urineF�
�� AUA�� !"#$%&'()*+',-./012�345
�� !"#$%&'()* 8�� !"#$%&'()*+,-.
�� !"#$%&'()*+,-./01234&5'�67Eα-
blockerF�� !5-α�� �� E5-α reductase inhibitorsF�� !"#
�� !"#$7�� !"#$%&'(Ewatchful waitingF�� !"
�� !
�� !"#$%&'()*+,-68%�� !"#�$%&'
50%�� !"#$%&'()*+,-./01234567289
�� !"#$%&'()*+,-./012)3456789:)
�� !"#$%&'()*+,-./012345 �(6708
�� 5-� �� !"#$%&'()*+,-./01'23!
�� !"#$%&'()EantimuscarinicsF�� !"#$%&'()
�� !�Epostvoid residual urine, PVRF�� !"#$%&'()*!
�� !"#$%&'()*+
�� !"#$%&'()*+,-./0#$12345
EhermaturiaF�� !"#$%&'()�*+�,-�./0123"
��
NMM
�� !"#$%&'()*+,
LUTS cause little or nobother (IPSS< 7)
Predominant nocturia
Frequency volume chart
Reassurance and F/U
Polyuria24-hour output ≥ 3 litersLife style modification
Fluid restriction
Nocturnal polyuria≥ 33% urine output at night
Fluid restrictionConsider desmopressin
SurgeryIndication matched
Recommended test for LUTSMedical history, LUTS severity (IPSS) and
bother score, DRE, PSA, UrinalysisVoiding diary (Option)
Further evaluationBothersome LUTS (IPSS > 8)
Recommended testFlow rate, Residual urine
Optional testSuprapubic echo or TRUS, UDS, Cystoscopy
Suggestive of BPO
SignificantBPO
Mixed OAB andBPO
Depends on size and anatomy of prostateα-blockers + / - 5α- Reductase inhibitors
Failure
Offer minimal invasive surgical treatment or Surgery
Complicated LUTSSuspicious DREHematuriaAbnormal PSAPainInfectionPalpable bladderNeurological disease
OABNo evidence of BOO
Cite OABguideline
First treatmentα-blockers + / -
5α- Reductase inhibitorsSecond treatment
+ / - Antimuscarinics (excludehigh risks)
� NK=�� !"#$%&'()*+,-./0 123456789:;<=
�� !"#$%&'()*+,-./0123456*789:;
�� !"#$
�� Enocturia symptomF�� !"#$%&'()*+,-./
�� !"#$%&'()�*+,-�./01234�5 678
�� !"#$%&'()*+,-.%/01!"234#5�67
�� !"#$%&'()*+,-./*0*1231456'7
EpolyuriaF�� !"#$�%&'()*+,-./0!123456
�� !"#$%&'()*+Enocturnal polyuriaF�� !"#$%&
�� !"#$%&'()*+,-./EdesmopressinF�� E� 1F�
�� !"#$%&
�� !"#$%&'()*+,-E1F�� !"#$%&'()
�� !"#$%&'()*+,-./0 !12345678'9
�� !"#$%&'()*+,-./0xChapple et al , 2008;
Madersbacher et al, 1999; Tong, 2007; Neal et al, 1987z�E2F�� !"#
�� !"#$%Eurinary tract infection, UTIF�� !"#$%&'(
�� !"#$%&$'()*+$,-./E3F�� !"#$%&'
�� !"#$%& !"'()*+ !",-./E4F�� !"#
�� !"#$%&'()*+,-./012,3456"789:
�� Evoiding timeF=�� !"Eflow patternF�� !"#$%&'(
�� !"#$%&'()*+,-. 150 mL�� !"#$%& 15
mL/sec�� !"#$%&' ()*+,-./ 10 mL/sec �� 88%
�� !"#$%&'()*+,-./10-14 mL/sec�� 57%��
�� !"#$%& 15 mL/sec � 33%�� !"#$%xGrino et al,
1993; Siroky et al, 1980; Drach et al, 1979; Abrams, 1977z�E5F��
E u l t r a s o u n d F�� !"#$%&'()*+,-./01234
EcalcificationF�� !"#$%&'()*+,-./012345,'
�� !"#$%&'()*+,-./012'34!5%&'6)
�� !"#$%&'()*+,-./01234#56"789:
�� xDoo and Uh, 2009; Rigatti et al, 2007; Bosch et al, 2008z�E6F��
�� Epressure-flow studyF�� !"#$%&'()*+,-./01
�� !"#$%&'()*+',-'./01234567*8
�� !"#$%&'()*xOelke et al, 2008; Lim et al, 1994; Zhang et
al, 2008; Dib et al, 2008z�
NMN
�� !"#$%&'()*+,
��
��
�� �!
�� !"#$%&'()*+,-./0E1F�� !Eserum
creatinineF�� !"#$%&'()*+,-./01234/56�
�� !"#$% 2%�� !"#$%&'()Esilent renal insuffi-
ciencyF�� !"#$%&'()*+,E2F�� !"#$Eurine
cytologyF�� !"#$%&'()*+,-./012345678
E3F�� !"#$%&'()�*+,-./01210�� !"#$
�� !"#$%&'xMadersbacher et al, 2004; AUA Practice Guidelines
Committee, 2003z�� !"#$%&'()*�+,-.(/0123
�� !"#$%&'()*+,-./01�234%56789:
�� !"#$%&'()�*+,-./0123456789
�� !"#$%&'()*+�� ,-./01234(56
�� !"#$%&$'()*+,-!./$012345,6!.
�� !"#$%É urinary retention, AURF�� !"#$%&'
�� !"#$%&xRoehrborn, 2000z�� !"#$%&'()*+
25%�� !"#$%&'() !"*+,-./4 ng/mLxPolascik et
al, 1999z�� !"#$%&!'()Evideourodynamic studyF�� !
EcystoscopyF�� !"#$%&'()*+,
�� !
�� !"#$%&'()*+,-./0123456789-
�� !"#$%&'()*+,-. 20%-30%�� !"#$%&
20%-50%�� !"#$%&'()�*+,-./012'34
xClifford and Farmer, 2000; Lowe and Reynolds, 1999; De la Rosette et al,
2 0 0 1 z�� !"#$%&'()*+,-./0123456
Doxazosin�� !"#$%Tamsulosin�� !"#$%&'()*5-
� �� !"#$%&'() Finasteride �� Dutasteride��
�8%�� !"#$%&'()*+,-./012345675-α�
� �� !"#$%&'()(*+$,-./01234$567
�� !"#$%&'()*+xRosen et al, 2005z�
�� !"#$%&'()*+,-.�/0123456789
�� !"#$%&'()*+�,-Eerectile dysfunction, EDF��
�� !"#$%&'()Enon-insulin dependent DM, NIDDMF�� !
�� !"#Echronic renal inusfficiencyF�� !"#$%&'()*+
�� !"#$%&'()*+,-.%/0123456781Modi-
fied-release formulations�� !Alfuzosin�Doxazosin�Tamsulosin�
�� !"#$%&'()*+,-./01*+234"$5%�6
�� !"#$%&'()*+,-./012345 Alfuzosin �
Tamsulosin�� !"#$%&'α1b�adrenergic receptors�� !"
�� !"#$%&'()*#$+,-./01234Tamsulosin�
�� !"#$%&xBarendrecht et al, 2005z�
�� !"#ECombination therapyF
��MTOP�� !"#$%&'()*+,-./01235-α
�� �� !"#$%&'()67%�� !"#$%&'()*+
�� !"#$%&'()xYoung et al, 2002z�� !CombAT��
�� !"#$%&'()*+,-./�0!123456!789
�� !"#$%� !&'()*+,-./012345#678
�� !"#$%&'(�)*CombAT�� !"#$%&'()*
�� !"#$%&'(!")*$+,-./01 !"#$%&'
�� !"#$%&'()*+,-./ 5-� �� Dutasteride
�� !"#Tamsulosin�� !"#$%& 5-� �� !"#
�� !"#$%"&'( 20%-27.3%�� !"#$ 2-6�� !"
�� !"#$%&'()*+,-./012345678901:
�� !"#$%&xMarberger, 1998; McConnell et al, 1998; McConnell
et al, 2003; Roehrborn et al, 2002; Boyle et al, 2004z�� !"#$%!&
�� !"#$%&'()Paul Abrams�Dr. Lee�� !"#$"%
�� !"#$%&'()*+ 3.3%�� !MTOP�� !"#$
�� !4�� !"#$%&'()*+ ,-./012.4%��
�� !"#$%&'()*+,-./+01(23456$789
�� !"#$%&'()*+,-./0123430%-40%�� !
�� !50-150cc�� !"#$%&'()xAbrams et al, 2001; Lee et
al, 2004; Athanasopoulos et al, 2003; Gonzalez and Te, 2003z�
��
�� !"#$%&'()*+,'-./0/1*2345/0
�� !"#$%&'()*+,-.�/ 0123456789:
�� xBlanker et al, 2000z�� !"#$%&'()*+#,-$./
�� !"#$%&'()*+,-./01234567Efrequency-
volume chartF�� !"#�$%!&'()*+,-./01!234
�� !"#$� %&'$()#$*+,-./01� 2345
E� 2F=�
Nocturia
Bothersome?Yes
Exclude
Co-morbidities
Medication effect
Sleep disorder
Environmental problem
Frequency-volume chart
Overactivebladder syndrome
Bladder outflowtract obstruction
Polyuria/nocturnalpolyuria
Rx
No
Rx Rx
Simple advice
� 2K �� !"#$%&'()*+,[Wagg A et al, 2005]�
��
��
��
NMO
�� !"#$%&'()*+,
��
�� !ESurgeryF
�� !Eminimally invasive treatment, MITF�� !"#$%&'
�� !Etrans-urethral microwave thermotherapy, TUMTF�� !"#$
�� !Etrans-urethral needle ablation, TUNAF�� !"Elaser therapyF�
�� !"#$%Egreen light laserF�� !"#$%&'()*+,�
�� !"#$%&'()*+,-./Etrans-urethral resection of
prostate, TURPF�� !"#$% 1992�� !"#$%&'()!
�� !"#2004�� !"#$%&'()*+,-./01234
�� !"#$%1962��2.5%�� !"#0.1%�� !"#$%
1962��18%��11%�� !"#$%&'5.8%�� !"#$%
� 5.6%�� !"#$%&'�(")*+,-! 9.8%�� !"#
�� ! 22%xMartin M, 2009z�
�� !"#$%&'()*500�� !"#$%&'()*+
�� !"#$%&'10%�� !"#$%&'()*+,-./0
�� !"#$%&'()*#+,-./0123456718�9
�� !"#$%&'()*+ 5.2%�� !"#$%6.8%�� !
�� !"#$%&'()*+,-./01234567.89:
�� !"#$%&'()*+,-EAspirinF�� !"#$%&'()
�� !"#$%&'()*+,-./0123456$789:4
�� !"#$%&'()*+,-./012$%&'()3456
�� !"#$%&'()*+,-./012 34 56xRuszat et
al, 2008; Kuntz, 2006 z�
�� !ESelf managementF
�� !"#$%&'(E1F�� !"#$% !&'()*+,
�� !"#$%&' ()*+,-./012()*34+567
�� !"#$%&'()*�+#,)-%&./01)23456
�� !"#E2F�� !"#$%&'()*+�� !, 1500-2000
mL�� !"#$%&'()*+ ,-./01234567 38
�� !"#$%&'()*�#+,-� ./012#3�4+,
�� 2�� !"#$%&'()*+,-E3F�� !"#$%&
�� !"#$%&'()�*+,-."#$/012345E4F��
�� !"#$%&'()* +,-./0/1E5F=�� !"#$%
�� !"#$%&'()*+,� -./012345678&9
�� !"#$%&xBrown et al, 2004; Emberton M, 2006z�
�� !EPrevention therapyF
�� Permixon�Finasteride�� !"#$%&'()*+,-
�� !"Permixon�� !"#$%&'()*+,-./0123
�� !"#$%&'(")*+,-(./0123456Permixon
�� !"#$%&'()*+,-./01 !23456%,-5-
� �� !"#$%&'()*+,-./012345678
�� !"#$%&'�()*+,�-./
�� !
Abrams P, Kaplan S, Millard R: Tolterodine treatment is safe in menwith bladder outlet obstruction (BOO) and symptomatic detrusor
overactivity (DO). Neurourol Urodyn 2001; 20:547-548.Abrams PH: Prostatism and prostatectomy: The value of urine flow rate
measurement in the preoperative assessment for operation. J Urol1977; 117:70-71.
Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P,Barbalias G: Combination treatment with an alpha-blocker plus ananticholinergic for bladder outlet obstruction: A prospective,randomized, controlled study. J Urol 2003; 169:2253-2256.
AUA Practice Guidelines Committee: AUA guideline on management ofbenign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treat-ment recommendations. J Urol 2003; 170:530-547.
Barendrecht MM, Abrams P, Schumacher H, de la Rosette JJ, MichelMC: Do alpha1-adrenoceptor antagonists improve lower urinary tractsymptoms by reducing bladder outlet resistance? Neurourol Urodyn2008; 27:226-230.
Barendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC: Treat-ment of lower urinary tract symptoms suggestive of benign prostatichyperplasia: The cardiovascular system. BJU Int 2005; 95(Suppl 4):19-28.
Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, RuudBosch JL: Normal voiding patterns and determinants of increased di-urnal and nocturnal voiding frequency in elderly men. J Urol 2000;164:1201-1205.
Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM: The long-termrelationship between a real change in prostate volume and a signifi-cant change in lower urinary tract symptom severity in population-basedmen: The Krimpen study. Eur Urol 2008; 53:819-827.
Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, EmbertonM: 5-alpha reductase inhibition provides superior benefits to alphablockade by preventing AUR and BPH-related surgery. Eur Urol 2004;45:620-627.
Brown CT, van der Meulen J, Mundy AR, O'Flynn E, Emberton M: De-fining the components of a self-management programme for men withuncomplicated lower urinary tract symptoms: A consensus approach.Eur Urol 2004; 46:254-263.
Chapple GR, Wein AJ, Abrams P, et al: Lower urinary tract symptomsrevisited: A broder clinical perspective. Eur Urol 2008; 54:563-569.
Clifford GM, Farmer RD: Medical therapy for benign prostatic hyperplasia:A review of the literature. Eur Urol 2000; 38:2-19.
De la Rosette JJ, Alivizatos G, Madersbacher S, et al: EAU Guidelineson benign prostatic hyperplasia (BPH). Eur Urol 2001; 40:256-264.
Dib PT, Trigo-Rocha F, Gomes CM, Srougi M: Urodynamic evaluationin diabetic patients with prostate enlargement and lower urinary tractsymptoms. Urol Int 2008; 80:378-382.
Doo CK, Uh HS: Anatomic configuration of prostate obtained bynoninvasive ultrasonography can predict clinical voiding parametersfor determining BOO in men with LUTS. Urology 2009; 73:232-236.
Drach GW, Layton TN, Binard WJ: Male peak urinary flow rate: Rela-tionships to volume voided and age. J Urol 1979; 122:210-214.
Emberton M: Patient-led management of BPH: From watchful waiting toself-management of LUTS. Eur Urol Suppl 2006; 5:704-709.
Gonzalez RR, Te AE: Overactive bladder and men: Indications foranticholinergics. Curr Urol Rep 2003; 4:429-435.
Grino PB, Bruskewitz R, Blaivas JG, et al: Maximum urinary flow rate byuroflowmetry: Automatic or visual interpretation. J Urol 1993; 149:339-341.
Kuntz RM: Current role of lasers in the treatment of benign prostatichyperplasia (BPH). Eur Urol 2006; 49:961-969.
Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB: Comparisonof doxazosin with or without tolterodine in men with symptomatic blad-der outlet obstruction and an overactive bladder. BJU Int 2004; 94:817-820.
Lim CS, Reynard J, Cannon A, Abrams P: The Abrams-Griffith number:A simple way to quantify bladder outflow obstruction. Neurourol Urodyn1994; 13:475-476.
NMP
�� !"#$%&'()*+,
Lowe PA, Reynolds CR: Age, gender, and education may have littleinfluence on error patterns in the assessment of set-shifting and ruleinduction among normal elderly. Arch Clin Neuropsychol 1999; 14:303-315.
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de laRosette JJ: EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benignprostatic, abstruction (BPH Guidelines). Eur Urol 2004; 46:547-554.
Madersbacher S, Pycha A, Klingler CH, Schatzl G, Marberger M: TheInternational Prostate Symptom score in both sexes: A urodynamics-based comparison. Neurourol Urodyn 1999; 18:173-182.
Marberger MJ: Long-term effects of Finasteride in patients with benignprostatic hyperplasia: A double-blind, placebo-controlled, multicenterstudy. Urology 1998; 51:677-686.
Martin M, de la Rosette J: Medical treatment of lower urinary tract symp-toms suggestive of benign prostatic hyperplasia. Eur Urol Suppl 2009;8:496-503.
McConnell JD, Bruskewitz R, Walsh P, et al: The effect of Finasterideon the risk of acute urinary retention and the need for surgical treat-ment among men with benign prostatic hyperplasia. N Engl J Med1998; 338:557-563.
McConnell JD, Roehrborn CG, Bautista OM, et al: The long-term effectof Doxazosin, Finasteride, and combination therapy on the clinical pro-gression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
Neal DE, Styles RA, Powell PH, Ramsden PD: Relationship betweendetrusor function and residual urine in men undergoing prostatectomy.Br J Urol 1987; 60:560-566.
Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Hofner K: Ageand bladder outlet obstruction are independently associated with de-trusor overactivity in patients with benign prostatic hyperplasia. EurUrol 2008; 54:419-426.
Pleil A, Coyne K, Reese P, Jumadilova, Z, Kellehe C: Confirming thevalidity of patient global impression's as outcome measures in overac-tive bladder. Eur Urol Suppl 2005; 4:142.
Polascik TJ, Oesterling JE, Partin AW: Prostate-specific antigen: A de-cade of discovery - What we have learned and where we are going. JUrol 1999; 162:293-306.
Rigatti P, Cestari A, Gilling P: The motion: Large BPH should be treatedby open surgery. Eur Urol 2007; 51:845-848.
Roehrborn CG, Bruskewitz R, Nickel GC, et al: Urinary retention in pa-tients with BPH treated with Finasteride or placebo over 4 years.Char-acterization of patients and ultimate outcomes. The PLESS StudyGroup. Eur Urol 2000; 37:528-536.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G: Efficacy andsafety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride)in men with benign prostatic hyperplasia. Urology 2002; 60:434-441.
Ruszat R, Seitz M, Wyler SF, et al: GreenLight laser vaporization of theprostate: Single-center experience and long-term results after 500procedures. Eur Urol 2008; 54:893-901.
Rosen RC, Giuliano F, Carson CC: Sexual dysfunction and lower uri-nary tract symptoms (LUTS) associated with benign prostatic hyper-plasia (BPH). Eur Urol 2005; 47:824-837.
Siroky MB, Olsson CA, Krane RJ: The flow rate nomogram: II. Clinicalcorrelation. J Urol 1980; 123:208-210.
Tong YC: Comparisons of urodynamic findings and voiding habits inpatients with concomitant benign prostatic hyperplasia and detrusoroveractivity presenting with or without the symptom of urgency. UrolInt 2007; 78:219-225.
Wagg A, Andersson K-E, Cardozo L, et al: Nocturia: Morbidity and man-agement in adults. Int J Clin Pract 2005; 59:938-945.
Young HH, Frontz WA, Baldwin JC: Congenital obstruction of the poste-rior urethra. J Urol, 3: 289-365, 1919. J Urol 2002; 167:265-268.
Zhang K, Xu Z, Zhang J, Wang H, Zhang D, Shi B: Clinical significanceof urodynamic analysis in patients with benign prostatic enlargementcomplicated with diabetes mellitus. Urol Int 2008; 81:149-152.